Board summary
Key figures
95,394
Registered population
75.7% aged 18–64
8.8%
Aged 65+
ICB 14.9% · England 17.9%
45.2%
In IMD quintile 1
ICB 40.7% · England 21.0%
~33,732
Core20 residents (est.)
Resident basis; registered basis ~44,262 · see page 3
8,464
Hypertension register
+0.38% in 3 yrs · England +5.60%
1,072
SMI register
28.9% of Salford (LAD)'s
2,229
COPD register
Reviews +19.70% in 3 yrs
Forecast to 2030
9,020
Hypertension patients, 2030
+556 on today
68.8%
QRISK ≥20% on statins, 2030
+1.16pp over 3 yrs
2.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma review coverage grew faster than comparators.
Asthma annual reviews grew +30.3% from 2023 to 2025 (England +4.4%; Salford +18.5%), reaching 68.4% against 65.7% in England.
Stroke register contracted against comparator growth.
Stroke QOF prevalence changed by -6.3% from 2023 to 2025 (England +2.3%) to 1.3%, which may reflect coding or the 8.8% aged 65+ share.
Cervical screening coverage at ages 25-49 trails England.
Cervical screening at ages 25-49 is 56.3%, below Salford (62.7%), the ICB (65.9%) and England (66.8%), which may reflect recall or access barriers.
Population, age and ethnicity
Across 95,394 registered patients, 75.7% are aged 18–64 and 8.8% aged 65+
Salford South East PCN serves 95,394 registered patients. Adults aged 18–64 represent 75.7% (72,235 patients), exceeding Salford (LAD) at 64.8%, NHS Greater Manchester Integrated Care Board at 63.3%, and England at 62.7%. Those aged 65+ account for 8.8% (8,378 patients), below Salford (LAD) at 14.4%, the ICB at 14.9%, and England at 17.9%. Census estimates record 0.3% Roma and 0.2% Gypsy or Irish Traveller residents. Projected population growth to 2030 is 2.7% (Salford (LAD) 1.7%, ICB 1.6%, England 2.3%), though projection methodology is unverified. Age counts reflect registered patients, whereas ethnicity uses Census resident estimates.
Age profile
65+: ICB 14.9%, England 17.9%
Older people · falls rows are Salford (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Salford LA) | 2,980 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 86.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 60.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Salford LA) | 1,510 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Salford LA) | 15.7 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 coverage reaches 45.2% and concentration varies sharply across practices
Salford South East PCN has an average IMD decile of 3.7 (Salford 3.9, ICB 4.5, England 5.5) and 45.2% of registered patients in Core20 areas, above Salford (44.0%), the ICB (40.7%) and England (21.0%). Across practices, concentration spans a 69.7 pp range, peaking at The Willows Medical Practice (78.8%) and Cornerstone Medical Practice (71.1%). However, volume concentrates at Langworthy Medical Practice (10,935 estimated Core20 patients) and 1/salford Medical Practice (6,271). Practice estimates sum to 44,262 against 33,732 resident Core20 patients, requiring denominator reconciliation.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
1,072
SMI register
1.15% recorded prevalence
338
Learning disability register
0.36% recorded prevalence
13
Care homes, 330 beds
In the PCN catchment
9.2%
Provide unpaid care
Salford (LAD), Census 2021
The PCN records 1,072 patients on the severe mental illness register (1.1% versus Salford (LAD) 1.1% and England 1.0%), representing 28.9% of the borough register, and 338 patients on the learning disability register (0.4% versus England 0.6%). Catchment capacity includes 13 care homes with 330 beds.
Severe mental illness: physical health checks
SMI prevalence is 1.1% (England 1.0%). While annual BMI checks reach 88.1% (England 82.1%), blood pressure checks stand at 81.9%, trailing England (83.4%) and Salford (84.7%). Check components show strong BMI tracking but lagging blood pressure monitoring.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
8,464
Hypertension register
+0.38%
Register growth, 3 yrs
Salford (LAD) +5.45% · England +5.60%
+6.57pp
BP control, under 80
≤140/90 · +4.45pp aged 80+
+556
More patients by 2030
Forecast 9,020 (9.15%)
Hypertension case-finding and control
Recorded hypertension prevalence is 9.1% (8,464 patients), below Salford (12.4%), NHS Greater Manchester ICB (14.4%) and England (15.2%), with three-year growth of +0.4% trailing England (+5.6%). This lower crude rate is consistent with a younger list (8.8% aged 65+ versus England 17.9%), though case-finding variation cannot be excluded. Once registered, clinical control is strong: 92.4% have a recent blood pressure reading (England 90.0%) and 75.7% are treated to target (England 70.3%). Lower register growth alongside strong treatment control may reflect younger demographics or case-finding gaps, testable via age-standardised audits.
Lipids and statins
For patients with QRISK ≥ 20%, 66.4% receive lipid-lowering therapy, above England (63.6%), but three-year growth (+1.8%) lags England (+6.2%). In contrast, lipid prescribing for patients aged 65+ reaches 16,593 per 1,000, exceeding Salford (14,002). Slower therapy expansion than England among patients with QRISK ≥ 20% highlights an opportunity to review cardiovascular risk recalls.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 139,019 | £1.30 | £1.94 | £1.86 | £180,725 |
| Cardiovascular (all), 2025 | 195,745 | £2.34 | £3.15 | £3.33 | £458,043 |
In 2026, the PCN prescribed 139,019 lipid-regulating items at £1.30 per item, below Salford (£1.54), NHS Greater Manchester ICB (£1.94) and England (£1.86), which is £77,851 less than at England's unit cost across these items. Lower unit cost reflects formulary choices or case-mix rather than proven efficiency, providing context for prescribing spend.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+30.29%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−4.94%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 5.0% (England 6.6%), falling 4.9% from 2023 to 2025 (England +0.5%). COPD prevalence is 2.4% (England 1.9%), falling 2.6% (England +2.6%). Meanwhile, 12-month asthma reviews reached 68.4% (England 65.7%), leaving an estimated 1,391 patients unreviewed across the 4,408 register (a scale indicator). Asthma prescribing reached 2,152 items per 1,000 aged 5-19 (England 1,488). Contracting registers alongside higher youth prescribing may reflect diagnostic variation, testable by clinical audit.
Cancer register and children's immunisation
Cancer prevalence is 2.1% (England 3.8%), rising +3.7% from 2023 to 2025 (England +9.0%). In Q1 2025/26 childhood immunisations, MMR dose 1 at age five reached 95.0% (England 91.7%), but dose 2 was 84.2% (England 82.8%), a 10.8 pp same-cohort difference across 222 children. The second-dose gap may reflect recall barriers, testable by practice-level vaccination audits.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Greater Manchester ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,270
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Greater Manchester ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 15% | 2,193 |
| Prostate | 61.7% | 53.2% | 14% | 1,788 |
| Breast | 82.5% | 85.4% | 19% | 1,758 |
| Bowel | 46.3% | 47.0% | 19% | 1,427 |
| Skin cancer | 84.5% | 87.8% | 27% | 580 |
In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 known-stage cases; England 55.3%), sitting 19.4 pp below the 75.0% national ambition. Known stage was recorded for 70.8% of 16,492 cancers; staging is not published at PCN level. Reaching 75.0% requires about 2,270 additional early diagnoses across the ICB, where early diagnosis rose +3.1 pp from 2013 to 2022. Locally, PCN cervical screening is 56.3% (England 66.8%) and breast screening is 61.2% (England 69.9%). Lagging primary care screening uptake may reduce early detection opportunities across wider system pathways.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
Northern Care Alliance NHS Foundation Trust exceeded the 75.0% 28-day faster diagnosis standard by 0.2 pp (75.2044%), but fell 6.4 pp below the 85.0% 62-day referral standard at 78.6486% and 1.5 pp below the 96.0% 31-day standard at 94.5402%. Across NHS Greater Manchester Integrated Care Board, 28-day diagnosis reached 79.5261% (4.5 pp above) and 31-day treatment was 96.4937% (0.5 pp above), while 62-day referral was 9.3 pp below standard at 75.7262%. Slower treatment commencement following referral may prolong overall cancer pathways despite meeting the faster diagnosis standard.
| Pathways within standard (%) | Northern Care Alliance | Manchester | Bolton | Greater Manchester ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 75.20 | 80.06 | 80.48 | 79.53 | 79.32 |
| 31-day treatment (96%) | 94.54 | 92.54 | 96.50 | 96.49 | 92.50 |
| 62-day referral to treatment (85%) | 78.65 | 72.85 | 69.66 | 75.73 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Northern Care Alliance | Manchester | Bolton | England |
|---|---|---|---|---|
| MRI | 5.09 | 11.68 | 2.05 | 21.40 |
| CT | 4.10 | 14.66 | 19.40 | 9.92 |
| Echocardiography | 31.48 | 4.91 | 3.48 | 28.48 |
| Colonoscopy | 40.04 | 4.51 | 1.33 | 30.83 |
| Gastroscopy | 36.48 | 29.35 | 2.06 | 29.02 |
| All 15 DM01 tests | 15.71 | 8.98 | 15.78 | 23.14 |
| Community services activity | Salford residents | Greater Manchester ICB |
|---|---|---|
| Care contacts | 37,955 | 573,310 |
| Referrals | 3,340 | 94,470 |
| Patients with a contact | 15,440 | 183,535 |
Community services (residents of Salford), Jun 2026 (provisional). In provisional June 2026 data, adults aged 65 and over accounted for 53.9% of community service contacts among borough residents (20,470 of 37,955 contacts). Substantial older-adult community activity provides an entry point to coordinate local frailty reviews with early diagnostic pathways.
Practice variation and patient experience
Patient phone access varies across practices by 27.4 pp, alongside uneven vaccination achievement
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Orient Road | 111 | 9.1 | 81.6% | 77.4% | 87.7% |
| Cornerstone | 118 | 71.1 | 83.6% | 88.4% | 87.3% |
| Sorrel Bank | 116 | 41.2 | 56.3% | 83.1% | 83.0% |
| Ordsall Health | 122 | 33.8 | 65.3% | 80.8% | 81.5% |
| Clarendon Surgery | 101 | 52.7 | 67.8% | 64.4% | 80.5% |
| Langworthy | 121 | 60.7 | 59.1% | 73.2% | 79.0% |
| 1/salford Medical | 113 | 38.0 | 79.6% | 77.4% | 78.9% |
| Willows Medical | 106 | 78.8 | 82.4% | 70.3% | 77.6% |
| Height General | 128 | 22.6 | 66.0% | 72.1% | 76.3% |
| Pendleton | 104 | 66.5 | 61.8% | 77.3% | 72.8% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Contracting stroke and learning disability registers lead 11 measures trailing England
Across 25 compared measures, 11 trailed England's 2023 to 2025 change. Slower progress was led by contracting registers: stroke prevalence fell 6.3% (Salford (LAD) +1.5%, England +2.3%), learning disability fell 1.1% (England +5.4%), and asthma fell 4.9% (England +0.5%). Conversely, clinical review processes showed strong relative growth, including asthma reviews (+30.3% versus England +4.4%) and COPD reviews (+19.7% versus England +2.8%), alongside BMI recording on the mental health register rising 20.7 pp (England +5.1 pp). Slower register expansion could reflect case-finding gaps or age structure, testable by clinical audits.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Stroke register
Learning disability register
Asthma register
COPD register
Cancer register
Asthma reviews
COPD reviews
BMI record (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Salford (LAD) | Asset | PCN | Salford (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 13 (330 beds) | n/a | Schools (catchment) | 93 | n/a |
| Children's centres | 6 | 16 | Places of worship | 33 | 118 |
| Libraries | 5 | 16 | Primary schools (LA maintained) | 17 | 52 |
| Primary academies | 5 | 21 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Stroke register and coding audit
Recorded stroke prevalence is 1.3% (1,213 patients) versus Salford (LAD) 1.7% and England 1.9%, falling 6.3% from 2023 to 2025 (England +2.3%), with a modelled unadjusted gap range of +419 to +589. Low cost, quick to run.
Evidence base: the stroke/TIA register is the cohort for AF anticoagulation and blood-pressure control (pre-stroke prevention) as well as hyperacute care; practices well below expected prevalence are the case-finding list, and the pre-stroke prevention gap concentrates in deprived practices.
Policy anchor: Core20PLUS5 (CVD); NHS CVD ambitions to 2029.
Option 2
Learning disability register validation
Learning disability prevalence is 0.4% (338 patients) versus Salford (LAD) 0.5% and England 0.6%, falling 1.1% from 2023 to 2025 (England +5.4%), with a modelled gap range of +129 to +223. For discussion: practices could audit historical diagnostic codes and cross-check registers where local social-care data-sharing agreements exist. Moderate effort to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Option 3
Structured asthma annual review recall
Annual asthma reviews reached 68.4% (above England 65.7%, but 3.2 pp below Salford (LAD) 71.6%), leaving an estimated 1,391 of 4,408 registered patients without a recorded 12-month review. For discussion: practices could standardise recall templates, align inhaler prescribing checks with annual reviews, and offer flexible appointment slots. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI cardiovascular check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension case-finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS good overall experience of the practice | 10YHP, hospital to community | Practice |
| Option 1 · Stroke register and coding audit (p12) | Stroke register · Stroke: QOF prevalence · Aged 65+ | Core20PLUS5 CVD · CVDPREVENT · SSNAP | PCN |
| Option 2 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
| Option 3 · Structured asthma annual review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
